GATC Health

GATC Health is a tech-bio company founded in 2020 and headquartered in Irvine, California, that is advancing drug discovery and disease prediction through its proprietary artificial intelligence platform. The company was co-founded by President Jeff Moses, Chief Technology Officer Jayson Uffens, and Chief Science Officer Ian Jenkins. Jenkins' background includes work on the Human Genome Project, while Uffens has experience on large-scale projects with companies like GrubHub and the Department of Defense.

The core of GATC Health's offering is its Multiomics Advanced Technology™ (MAT) platform, which utilizes AI, machine learning, and neural networks to simulate human biology. This platform can analyze vast biological datasets—including genomics, proteomics, and metabolomics—to identify novel drug targets, create new therapeutic candidates, and predict their safety and efficacy before lab testing. The MAT platform can process 400 trillion data points in under eight minutes and has been validated by the University of California, Irvine, demonstrating high accuracy in predicting drug success. This capability aims to significantly reduce the time and cost associated with the traditional drug development process, which can take over a decade and cost more than a billion dollars per drug.

GATC Health's business model involves multiple revenue streams. It develops its own pipeline of novel drug candidates for diseases such as opioid use disorder, PTSD, and cancer. The company also partners with pharmaceutical and biotech companies to accelerate their drug development programs, de-risk their pipelines, and even reassess previously failed assets. A significant partnership involves a collaboration with Medical and Commercial International (MCI), a Lloyd's of London syndicate, to provide the world's first insurance coverage for clinical trials. GATC's platform forecasts trial endpoints, enabling MCI to underwrite the financial risk of trial failure, a development intended to transform the drug development financial model.

The company serves clients across the healthcare spectrum, including pharmaceutical companies, biotech firms, health plans, providers, and government entities. GATC Health has raised $22.3M in funding and has established an East Coast presence at the WVU Innovation Corporation facility in Morgantown, West Virginia, to expand its lab operations.

Keywords: artificial intelligence, drug discovery, multiomics, predictive analytics, biotechnology, computational biology, personalized medicine, clinical trials, pharmaceutical development, genomics